Online ISSN: 2515-8260

Keywords : Saroglitazar


Efficacy of Saroglitazarin patients with diabetic dyslipidemia

Surendra Kumar Ghintala, Pradeep Kumar, Ajeetkumar Gadhwal, Ratan Kumar Agarwal

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 1, Pages 243-247

Background:Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder
characterized by persistent hyperglycaemia due to relative insulin deficiency, insulin
resistance. This study assessed efficacy of Saroglitazar in patients with diabetic
dyslipidemia
Materials & Methods:120 patients with type 2 diabetes mellitus of both genders were
assessed for serum fasting plasma glucose, post prandial glucose, glycated hemoglobin
(HbA1c), blood urea, serum creatinine, S.G.O.T, S.G.P.T and lipid profile. Patients were
treated with Saroglitazar 4 mg once daily and the follow-up data were available for 12
months.
Results: Out of 120 patients, males were 80 and females were 40. The mean triglyceride
level was 610.4, 208.4 and 224.4, total cholesterol was 312.2, 244.7 and 172.1, non- HDLC
was 274.8, 199.6 and 126.3, LDL- C was 165.6, 116.8 and 104.17, HDL- C was 41.4, 42.1
and 42.5, HbA1C was 8.02, 7.8 and 7.1, FPG was 156.2, 130.5 and 120.4, PPG was
234.6, 172.1 and 160.5, SGOT was 46.6, 42.3 and 40.3, SGPT was 34.2, 38.4 and 37.4, S.
Creatinine was 0.7 and CPK was 74.3, 71.6 and 68.3 at baseline, 12 wees and 52 weeks
respectively. The difference was significant (P<0.05).
Conclusion: Saroglitazar is a very effective therapeutic option in diabetic dyslipidemia with
very high triglycerides level.